The in vitro activity of a unique new 1-oxa cephalosporin beta-lactam antibiotic (LY 127935) Recently, a number of new cephalosporins have been introduced which have expanded the antibacterial spectrum of this class of antimicrobial agents [1, 2] . One of these compounds, (6R, 7R)-7{ (Carboxy(4-hydroxyphenyl) acetyl) amino]-7-methoxy-3-[(1-methyl-iH-tetrazol-5-yl) thio) methyl]-8-oxo-5 oxa-I azabicyclo-[4.2.0] oct-2-ene-2 carboxylic acid (LY 127935), is a new beta lactam antibiotic. Structurally, this compound contains a conventional cephem nucleus in which oxygen is substituted in place of sulfur in the six-membered ring [3] .
Recently, a number of new cephalosporins have been introduced which have expanded the antibacterial spectrum of this class of antimicrobial agents [1, 2] . One of these compounds, (6R, 7R)-7{ (Carboxy(4-hydroxyphenyl) acetyl) amino]-7-methoxy-3-[(1-methyl-iH-tetrazol-5-yl) thio) methyl]-8-oxo-5 oxa-I azabicyclo-[4.2.0] oct-2-ene-2 carboxylic acid (LY 127935), is a new beta lactam antibiotic. Structurally, this compound contains a conventional cephem nucleus in which oxygen is substituted in place of sulfur in the six-membered ring [3] .
The purpose of this study was to characterize more thoroughly the in vitro activity of this new antibiotic against a wide variety of gram-negative and gram-positive organisms isolated from patients and to compare their activity to the antimicrobial activity of agents currently in clinical use. Specifically, the in vitro activity of LY 127935 was compared to that of cefoxitin, cephalothin, cefamandole, carbenicillin, ticarcillin, gentamicin, tobramycin, amikacin, and clindamycin.
MATERIALS AND METHODS Antibiotics
Ten antibacterial agents were tested and were kindly supplied as laboratory standards by their manufacturers. Gentamicin was supplied by Schering Corporation, Bloomfield, NJ; tobramycin, cefamandole, keflin, LY 127935 were forwarded from Eli Lilly and Company, Indianapolis, IN; amikacin came from Bristol Laboratories, Syracuse, NY; cefoxitin was supplied by Merck, Sharpe and Dohme, West Point, PA; ticarcillin was supplied by Beecham Laboratories, Bristol, TN; carbenicillin came from Roerig, New York, NY; and clindamycin was supplied by Upjohn Company, Kalamazoo, MI. Dilutions of the antibiotic were prepared fresh in sterile growth medium and used the same day.
Bacterial Strains
Fifteen strains each of Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Serratia marscescens, Enterobacter species, indole positive Proteus, indole negative Proteus, penicillin sensitive Staphylococcus aureus, penicillin resistant Staphylococcus aureus, and Group D Streptococci were clinical isolates used in this study. These strains were obtained from patients hospitalized within the past year at Yale-New Haven Hospital and the West Haven Veterans Administration Hospital. All fifteen strains of penicillin resistant S. aureus showed minimal inhibitory concentrations (MIC) of penicillin (Eli Lilly and Co., Indianapolis, IN) equal to or greater than 512 ug/ml as determined with the microtiter method outlined below. Penicillin sensitivity among S. aureus strains was defined by a zone of inhibition of at least 29 mm around a 10 IU penicillin impregnated disc, using standard Kirby-Bauer technique [4] .
In Vitro Testing
For MICs, eleven twofold serial dilutions of each antimicrobial in trypticase soy broth (TSB) (BBL, Inc., Cockeysville, MD) were prepared [5, 6] . The highest concentrations of each drug tested were as follows: gentamicin and tobramycin, 32 ug/ml; amikacin, cefoxitin, cephalothin, cefamandole, and LY 127935, 128 ug/ml; ticarcillin and carbenicillin, 512 ug/ ml; clindamycin, 64 ug/ ml. The dilutions of each antimicrobial were applied to a 33/% x 41/4 inch microtiter plate containing 96 wells arranged in eight rows of twelve wells each. Each well was loaded with 0.1 ml of the appropriate drug dilution with a semi-automated pipettor (Dynatech, Inc., Alexandria, VA). One column of wells on each plate contained drug-free medium as a growth control. Each well was inoculated with 104 colony forming units (105 cfu/ ml) using an automated inoculator (Dynatech, Inc., Alexandria, VA). Eighteen-hour broth cultures of each organism were adjusted by visible light colorimetry in order that proper final inoculum densities were obtained. At the end of 18-24 hours' incubation at 370 C, duplicate rows for each strain were compared and MICs recorded as the lowest concentration of antibiotic which showed no visual turbidity. Where duplicate rows differed by only one well, MICs were reported as the higher concentration. Duplicates that differed by more than one well were repeated until consistent results were obtained. Minimal bactericidal concentrations (MBC) were determined by transferring an aliquot from each well of an MIC plate to trypticase soy agar (TSA) (BBL, Inc., Cockeysville, MD) poured into single-well 3% x 41/4 inch trays with the automated inoculating system previously described. The MBC was the concentration at which no colonial growth appeared after 24 hours of incubation at 370 C.
Inoculum Density and Media Testing
In order to determine effects of varying inoculum cell density and media, cephalothin, cefoxitin, cefamandole, and LY 127935 vs. all 150 organisms were tested in the following combinations: (1) 1 x 107 cfu/ ml in TSB; (2) 1 x 105 cfu/ ml in Mueller-Hinton broth (MHB); (3) 1 x 107 cfu/ml in MHB as well as with 1 x 105 cfu/ ml in TSB as described above and MICs and MBCs were determined.
RES ULTS
The comparative in vitro activities of the 1-oxa cephalosporin and other antimicrobical agents are shown in Table 1 . Against Pseudomonas species the I-oxa compound was more active than cefoxitin, cefamandole, cephalothin, and clindamycin, was comparable in activity to ticarcillin and carbenicillin, but was less active than the aminoglycosides, gentamicin, tobramycin, and amikacin. The I-oxa compound was also more active than cefoxitin, cefamandole, cephalothin, clindamycin, amikacin, tobramycin, gentamicin, ticarcillin, and carbenicillin against Klebsiella, Serratia, Enterobacter, and both indole negative and positive Proteus species, as well as E. coli. Furthermore, our results indicate that the I-oxa compound inhibited members of the Enterobacteriaceae at lower concentrations than did the older cephalosporin, cephalothin, or the newer ones, cefamandole and cefoxitin. In fact, the new I-oxa cephalosporin compound was the most active agent tested against Klebsiella, Serratia, Enterobacter, indole negative and positive Proteus species, and E. coli. For example, the new compound inhibited 50 and 90 percent of: Klebsiella species isolates at concentrations of 0.25 and 0.5 ug/ml, respectively; Serratia species isolates at concentrations of 0.5 and 8 ug/ ml respectively; Enterobacter species isolates at concentrations of 0.25 and 4.0 ug/ml, respectively; indole negative Proteus species isolates at concentrations of less than 0.12 ug/ml; indole positive Proteus species isolates at concentrations of less than 0.12 and 0.25 ug/ ml, respectively; and E. coli isolates at concentrations of less than 0.12 and 0.5 ug/ml, respectively. No other antibiotic tested in this study demonstrated such a high degree of in vitro activity against these bacterial isolates. However, the new compound was less active than the aminoglycosides against Pseudomonas species isolates. For example, 50 percent of the Pseudomonas isolates tested were inhibited by 16 ug/ ml of the new compound, a concentration comparable to carbenicillin, ticarcillin and gentamicin, but more than the concentration of tobramycin (2.0 ug/ ml) or amikacin (4.0 ug/ ml) required to inhibit the same number of isolates. Similarly, 90 percent of the Pseudomonas isolates were inhibited by the 1 -oxa compound at a concentration of 128 ug/ ml or less, which was lower than the concentrations of all other antimicrobial agents studied except for the aminoglycosides, and of these, tobramycin, at a concentration of 2.0 ug/ ml, was the most active.
Against non-beta lactamase producing isolates of Staphylococcus aureus the new compound was less active than cefamandole, cephalothin, clindamycin, tobramycin, and carbenicillin, and was comparable in activity to cefoxitin, amikacin, gentamicin, and ticarcillin. In fact, cephalothin and cefamandole were the most active agents against these staphylococcal isolates as well as against the beta-lactamase producing isolates of Staphylococcus aureus which were tested in this study. The new compound was more active against these beta-lactamase producing staphylococcal isolates than were the aminoglycosides and clindamycin, but was less active than the other cephalosporins including cefoxitin. Furthermore, the I-oxa compound had poor inhibitory activity against Streptococcus faecalis and was considerably less active than the older cephalosporin antibiotics. Specifically, concentrations of 128 ug/ ml of the new compound failed to inhibit the growth of any of the S. faecalis isolates tested in this study.
Effect of inoculum size and growth medium. The effect of inoculum size on the minimum inhibitory concentration of the cephalosporin compounds tested in this study is shown in Table 2 . In these experiments the inoculum size was increased a hundredfold to 107 cfu per ml in trypticase soy broth (TSB). Higher concentrations of each of the four cephalosporins were required to achieve inhibition of growth of the larger inoculum of the Enterobacteriaceae isolates tested in this study although no differences in MICs were observed against Pseudomonas species isolates. Similarly, the in vitro activity of these four cephalosporin antibiotics was not significantly increased by a hundredfold increase in inoculum size of both beta-lactamase and non beta-lactamase producing strains of Staphylococcus aureus. The higher inoculum of Streptococcus faecalis isolates resulted in the loss of inhibitory activity of cefoxitin and only slightly influenced the activity of cefamandole and cephalothin against these bacterial strains. The new I-oxa compound had no detectable activity against the isolates of Streptococcus faecalis either at the lower or higher inoculum tested in this study.
A comparison of the minimum inhibitory concentrations of these four cephalosporins in Mueller-Hinton broth at both the lower (105 cfu per ml) and higher (107 cfu per ml) inocula is shown in Tables 3 and 4 . Again the activity of the new I-oxa compound, as well as that of cefoxitin, cefamandole, and cephalothin was decreased against Klebsiella, Serratia, Enterobacter, indole negative and indole positive Proteus species, and E. coli in the presence of the higher inoculum of 1 x 107 cfu per ml in Mueller-Hinton broth as it was in trypticase soy broth (Tables 1 and 2 ). However, in contrast to the results observed in trypticase soy broth the activity of the I-oxa compound against Pseudomonas species isolates was decreased by the increased inoculum in Mueller-Hinton broth (Tables 2 and 4 ). Furthermore, the activity of all four cephalosporin antibiotics was also decreased by the increased inoculum of non beta-lactamase producing Staphylococcus aureus isolates in Mueller-Hinton broth but was not influenced by the larger inoculum of betalactamase producing strains (Tables 3 and 4 ). This effect was not seen when these isolates were tested with the higher inoculum in trypticase soy broth (Tables 1 and 2) . Also, the larger inoculum did not influence the activity of these cephalosporin compounds against Streptococcus faecalis isolates when tested in Mueller-Hinton broth (Tables 3 and 4 ), but the activity of cefoxitin against these isolates was decreased when the lower inoculum was tested in Mueller-Hinton broth as compared with trypticase soy broth (Tables 1 and 3) .
The new 1-oxa compound was bactericidal for most of the species of organisms studied and there was a minimal difference between MIC and MBC. Specifically, the MBC of the I-oxa compound was only twofold higher than the MIC for both betalactamase and non beta-lactamase producing Staphylococcus aureus isolates at inocula of 105 and 107 but only in TSB. In fact, the new compound was more active (lower MIC and MBC) against beta-lactamase producing strains of S. aureus in MHB 
DISCUSSION
The introduction of the "second generation" cephalosporins, cefamandole and cefoxitin, resulted in a significant increase in the antibacterial spectrum of the older "first generation" cephalosporins against many beta-lactamase-producing Enterobacteriaceae and Bacteroides isolates [3] . The new I-oxa cephalosporin compound evaluated in the present study represents one of a new group of compounds which can be referred to as "third generation" cephalosporins because these newer compounds further enlarge the spectrum of antibacterial activity of the general class of cephalosporin antibiotics to include isolates of Pseudomonas aeruginosa. The I-oxa cephalosporin compound in the present report has in vitro activity similar to another new "third generation" cephalosporin, cefotaxime (HR-756), against Enterobacteriaceae and has been shown to be twice as active as cefotaxime against Pseudomonas aeruginosa and Bacteroidesfragilis subspecies fragilis [2, 3] . Although we did not compare the in vitro activity of this new I-oxa compound to that of cefotaxime, the results of the present study indicate that this new I-oxa cephalosporin has a broad spectrum of activity against a variety of clinical isolates including gram-negative bacilli as well as staphylococci. It was the most active drug tested against Klebsiella, Serratia, Enterobacter, indole negative and positive Proteus species, and E. coli. Most of these isolates were inhibited by concentrations as low as 0.5 ug/ ml of this new compound. Furthermore, 50 percent of the clinical isolates of Pseudomonas species were inhibited by concentrations of 16 ug/ ml of this compound and, although less active than currently available aminoglycosides, this compound has the potential to be clinically effective in the treatment of infections caused by these bacteria.
The new compound was less active against both beta-lactamase and non betalactamase producing staphylococcal isolates than the older cephalosporins, cephalothin and cefamandole, which were the most effective agents tested in this study. However, thel-oxa compound was effective against all staphylococcal isolates tested at concentrations of 8.0 ug/ ml although it had no appreciable activity against Streptococcus faecalis isolates.
The in vitro activity of this new compound against Enterobacteriaceae, as well as that of the other cephalosporins tested in the present study, was influenced by inoculum size in both trypticase soy and Mueller-Hinton broth. This decrease in activity of the 1-oxa compound was also observed against isolates of Pseudomonas species in Mueller-Hinton but not in trypticase soy broth. The clinical significance, if any, of these latter observations requires further study.
The results of the present study indicate that this new 1-oxa cephalosporin has a broad spectrum of in vitro antibacterial activity which, except for staphylococcal isolates, far exceeds the activity of older cephalosporins, including those agentsparticularly cefoxitin and cefamandole-which recently became available for general clinical use. Furthermore, this new compound compares favorably with other antimicrobial agents, including aminoglycosides and antipseudomonal penicillins, against aerobic gram-negative enteric bacilli. Thus, this new antibiotic offers great
